Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Free Cash Flow (2018 - 2025)

TELA Bio has reported Free Cash Flow over the past 8 years, most recently at -$5.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$5.0 million for Q4 2025, up 36.36% from a year ago — trailing twelve months through Dec 2025 was -$28.7 million (up 32.68% YoY), and the annual figure for FY2025 was -$28.7 million, up 32.68%.
  • Free Cash Flow for Q4 2025 was -$5.0 million at TELA Bio, up from -$5.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TELA hit a ceiling of -$5.0 million in Q4 2025 and a floor of -$14.7 million in Q1 2024.
  • Median Free Cash Flow over the past 5 years was -$9.3 million (2021), compared with a mean of -$9.2 million.
  • Biggest five-year swings in Free Cash Flow: crashed 108.69% in 2022 and later surged 36.36% in 2025.
  • TELA Bio's Free Cash Flow stood at -$9.4 million in 2021, then dropped by 16.63% to -$11.0 million in 2022, then decreased by 2.49% to -$11.3 million in 2023, then surged by 30.75% to -$7.8 million in 2024, then surged by 36.36% to -$5.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$5.0 million (Q4 2025), -$5.9 million (Q3 2025), and -$8.0 million (Q2 2025) per Business Quant data.